Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

456
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
456
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

406
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
406
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

548
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
548
Hormonal Regulation01:33

Hormonal Regulation

32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

103
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
103

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surfaced-based detection of focal cortical dysplasia using magnetic resonance fingerprinting and machine learning.

Epilepsia·2025
Same author

Comments on "Preventive Effect of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality: A Korean Population Study".

Gastroenterology·2025
Same author

TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.

American journal of translational research·2025
Same author

Effect of the Microstructure of Carbon Supports on the Oxygen Reduction Properties of the Loaded Non-Noble Metal Catalysts.

Nanomaterials (Basel, Switzerland)·2025
Same author

TEA domain transcription factor 3 suppresses aortic and left ventricular remodeling via transcriptional activation of PDZ domain containing 1.

Biochemical pharmacology·2025
Same author

Prospects and challenges of salivary gland tissue engineering in Sjögren's syndrome.

Expert reviews in molecular medicine·2025

Related Experiment Video

Updated: May 16, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K

Unravelling soluble (pro)renin receptor-mediated endothelial dysfunction.

Lachlan G Schofield1, Juyi Zhao2, Yu Wang3

  • 1School of Biomedical Sciences and Pharmacy, College of Health Medicine and Wellbeing, University of Newcastle, Callaghan (Awabakal Country), 2308, New South Wales, Australia; Women's Health Research Program, Hunter Medical Research Institute, New Lambton Heights (Awabakal Country), 2305, New South Wales, Australia.

European Journal of Pharmacology
|April 5, 2025
PubMed
Summary

PRO20, an antagonist of soluble prorenin receptor (s(P)RR), effectively prevents s(P)RR-induced endothelial dysfunction by inhibiting the s(P)RR-Angiotensin II Type 1 Receptor (AT1R) complex. This suggests PRO20 as a potential therapeutic for preeclampsia.

Keywords:
(Pro)renin ReceptorAngiotensin II type 1 receptorPreeclampsia

More Related Videos

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.2K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.8K

Related Experiment Videos

Last Updated: May 16, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.2K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.8K

Area of Science:

  • Reproductive biology
  • Vascular biology
  • Endocrinology

Background:

  • Preeclampsia is linked to maternal endothelial dysfunction and hypertension.
  • Elevated soluble prorenin receptor (s(P)RR) levels are observed in preeclamptic pregnancies.
  • Recombinant s(P)RR causes hypertension and vascular dysfunction.

Purpose of the Study:

  • To investigate the effects of PRO20, an s(P)RR antagonist, on s(P)RR-induced endothelial dysfunction.
  • To examine the interaction between s(P)RR, PRO20, and the Angiotensin II Type 1 Receptor (AT1R).

Main Methods:

  • Human uterine microvascular endothelial cells (HUtMECs) were treated with s(P)RR, PRO20, Losartan (AT1R antagonist), or Aliskerin (renin inhibitor).
  • Endothelial dysfunction markers were assessed via immunoblot, qPCR, and ELISA.
  • Protein structure prediction and molecular docking were used to model s(P)RR-AT1R interactions.

Main Results:

  • PRO20 reduced s(P)RR-induced mRNA expression of endothelin-1, VCAM-1, and ICAM-1.
  • PRO20 prevented s(P)RR and preeclamptic serum-induced protein increases in endothelin-1 and VCAM-1.
  • Molecular modeling indicated PRO20 impairs s(P)RR-AT1R complex formation.

Conclusions:

  • Elevated s(P)RR contributes to endothelial dysfunction, partly via AT1R.
  • PRO20 inhibits s(P)RR-AT1R complex formation.
  • PRO20 shows therapeutic potential for preeclampsia and related conditions.